Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Citius Pharmaceuticals announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the 2026 Maxim Growth Summit (October 12-14) and the ThinkEquity Conference (October 15) in New York City. Presentations will cover recent developments including the ongoing commercialization of LYMPHIR, the CTCL immunotherapy launched in December 2025 by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR).
Key figures
- Lympir market estimate
- $400 million
- Citius pharma ownership of oncology
- approximately 71%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.